The overall objective of this WP is to characterise further the candidate peptide epitopes to be used in the DAVIAD vaccine. The WP will use established in vivo models to generate pharmacodynamic data in support of the CTA application and provide data for the Investigators’ Brochure.
- Determine the optimal posology in disease models
- Understand the impact of co-medication on the efficacy of the DAVIAD vaccine
- Determine the recognition of the GD peptide epitopes by human PBMC and antibodies
- Prepare a non-clinical regulatory package to support a CTA application